Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Amylin/Calcitonin Receptor Agonism (cagrilintide) Delays gastric emptying, reduces postprandial glucagon, and strongly promotes satiety Modulates appetite-regulating centers in the hindbrain, hypothalamus, and brain reward circuits, directly influencing food intake and choice May transiently activate the renin-angiotensin-aldosterone system with dose escalation, but without blood pressure or electrolyte derangements GLP-1 Receptor Agonism (semaglutide) Stimulates glucose-dependent insulin secretion and suppresses glucagon release to improve glycemic control Reduces appetite and ad libitum energy intake, with central effects on GLP-1R-expressing nuclei in hypothalamus and brainstem Delays gastric emptying and increases satiety, contributing to progressive bodyweight loss Pharmacokinetic Profile Route of Administration Subcutaneous Dosing Frequency Once weekly Route of Administration : Subcutaneous Injection Dosing Frequency: Once weekly Half -life: Cagrilintide: 7-8 days
It is being evaluated through Eli Lilly's Phase 3 TRIUMPH program
Nature, 243(5407), 352354
A 10ml vial of bacteriostatic water provides enough volume to reconstitute multiple peptide vials throughout a research cycle, while remaining compact and easy to handle in a laboratory setting
3, 3-Diindolylmethane induces ferroptosis by BAP1IP3R axis in BGC-823 gastric cancer cells
US$ 24.01
US$ 20.69
US$ 28.38
US$ 28.60
US$ 28.25
